Cargando…

Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation

BACKGROUND: Acid sphingomyelinase deficiency (ASMD) (also known as Niemann-Pick disease types A and B) is a rare and debilitating lysosomal storage disorder. This prospective, multi-center, multinational longitudinal study aimed to characterize the clinical features of chronic forms of ASMD and dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGovern, Margaret M., Wasserstein, Melissa P., Bembi, Bruno, Giugliani, Roberto, Mengel, K. Eugen, Vanier, Marie T., Zhang, Qi, Peterschmitt, M. Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111900/ https://www.ncbi.nlm.nih.gov/pubmed/33971920 http://dx.doi.org/10.1186/s13023-021-01842-0

Ejemplares similares

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)
por: Wasserstein, Melissa, et al.
Publicado: (2018)

Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency
por: McGovern, Margaret M., et al.
Publicado: (2017)

Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann–Pick disease types A, B and A/B)
por: Geberhiwot, Tarekegn, et al.
Publicado: (2023)

P1483: LONG-TERM IMPACT OF OLIPUDASE ALFA ENZYME REPLACEMENT THERAPY ON SPLEEN VOLUME AND HEMATOLOGIC MANIFESTATIONS IN CHILDREN AND ADULTS WITH CHRONIC ACID SPHINGOMYELINASE DEFICIENCY
por: Villarrubia, Jesus, et al.
Publicado: (2023)

Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
por: McGovern, Margaret M., et al.
Publicado: (2017)

Prevalence of Cancer in Acid Sphingomyelinase Deficiency
por: Mauhin, Wladimir, et al.
Publicado: (2021)

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial
por: Wasserstein, Melissa P., et al.
Publicado: (2023)

Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency
por: Breilyn, Margo Sheck, et al.
Publicado: (2021)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2021)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2022)

Acid sphingomyelinase deficiency: The clinical spectrum of 2 patients who carry the Q294K mutation and diagnostic challenges
por: Blümlein, Ulrike, et al.
Publicado: (2022)

Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2022)

Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2023)

Focal hepatic lesions in acid sphingomyelinase deficiency: Differential diagnosis between foamy macrophages aggregates and malignancy
por: Sechi, Annalisa, et al.
Publicado: (2021)

Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency
por: Thurberg, Beth L., et al.
Publicado: (2016)

Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
por: Wasserstein, Melissa P., et al.
Publicado: (2018)

PB2314: OLIPUDASE ALFA FOR ADULTS WITH ACID SPHINGOMYELINASE DEFICIENCY: IMPROVEMENTS IN CROSSOVER PLACEBO PATIENTS AND FURTHER IMPROVEMENTS IN ORIGINAL OLIPUDASE ALFA PATIENTS AFTER 2 YEARS IN ASCEND TRIAL
por: Villarrubia, J., et al.
Publicado: (2022)

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults
por: Lachmann, Robin H., et al.
Publicado: (2023)

Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency
por: Kubaski, Francyne, et al.
Publicado: (2022)

Novel breakthrough in the treatment of sphingomyelinase deficiency
por: Sultan, Wania, et al.
Publicado: (2023)

Eleven Famous Autopsies in History
por: Ficarra, Bernard J.
Publicado: (1942)

Apoptosis and signalling in acid sphingomyelinase deficient cells
por: Sillence, Dan J
Publicado: (2001)

Acid Sphingomyelinase Deficiency Ameliorates Farber Disease
por: Beckmann, Nadine, et al.
Publicado: (2019)

Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective
por: Pinto, Carolina, et al.
Publicado: (2021)

Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France
por: Mauhin, Wladimir, et al.
Publicado: (2022)

Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency
por: Wang, Neng-Li, et al.
Publicado: (2022)

Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency
por: Keatinge, Marcus, et al.
Publicado: (2023)

Dietary deficiency of iron--an extreme example.
por: McGovern, M. C., et al.
Publicado: (1995)

Aging: Shedding Light on Vitamin D Deficiency in Women
por: McGovern, Victoria
Publicado: (2004)

Sphingomyelinases and Liver Diseases
por: Insausti-Urkia, Naroa, et al.
Publicado: (2020)

Eleven /
por: Highsmith, Patricia, 1921-1995
Publicado: (1980)

Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination
por: Chami, Marwan, et al.
Publicado: (2017)

Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency
por: Cassiman, David, et al.
Publicado: (2019)

Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective
por: Pokrzywinski, Robin, et al.
Publicado: (2021)

Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency
por: Gaudioso, Ángel, et al.
Publicado: (2023)

Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry
por: Patterson, Marc C., et al.
Publicado: (2020)

Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls
por: Lea, Simon R, et al.
Publicado: (2016)

Acid sphingomyelinase deals the seal
por: Short, Ben
Publicado: (2010)

Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency
por: Gaudioso, Ángel, et al.
Publicado: (2023)

Eleven papers on analysis
por: Fedorjuk, M V, et al.
Publicado: (1963)

Cannot write session to /tmp/vufind_sessions/sess_atd1v9sou6b5e78i9jvi8fp25g